The Dual Role of Endothelin-1 and Angiotensin II in Disease Progression of Focal Segmental Glomerulosclerosis and IgA Nephropathy

IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) are rare primary glomerulopathies, though the incidence of IgAN is greater. Endothelin 1 (ET-1) angiotensin II (Ang II) implicated in development progression FSGS. Both conditions impact health-related quality life (HRQoL) may lead to kidney failure. FSGS both evidenced clinically by proteinuria, with a greater degree such associated more progressive disease shorter times Accordingly, reduction proteinuria patients these key target. Currently, treatments unsuccessful or only partially successful number patients. Immunosuppressant therapy first-line for utilised who remain at high risk despite maximal supportive care; however, while effective, there significant toxicity relapse frequent. A clinical trials ongoing investigate use non-immunosuppressive agents management conditions. The dual endothelin Type receptor/Ang subtype receptor (ETAR/AT1R) antagonist (DEARA) sparsentan currently being assessed as means control progression. Interim study results show that can reductions than AT1R antagonism alone reaching partial remission (PR) Herein, symposium leading experts European Renal Association (ERA) 59th Congress Paris, 19th?22nd May 2022, presented. It highlights role conditions, how targeting ET-1 Ang potential PR.